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The MICs of ciprofloxacin for 33 clinical isolates of K. pneumoniae resistant to extended-spectrum cepha-
losporins from three hospitals in Singapore ranged from 0.25 to >128 g/ml. Nineteen of the isolates were
fluoroquinolone resistant according to the NCCLS guidelines. Strains for which the ciprofloxacin MIC was
>0.5 g/ml harbored a mutation in DNA gyrase A (Ser833Tyr, Leu, or IIe), and some had a secondary
Asp873Asn mutation. Isolates for which the MIC was 16 g/ml possessed an additional alteration in ParC
(Ser803IIe, Trp, or Arg). Tolerance of the organic solvent cyclohexane was observed in 10 of the 19 fluoro-
quinolone-resistant strains; 3 of these were also pentane tolerant. Five of the 10 organic solvent-tolerant
isolates overexpressed AcrA and also showed deletions within the acrR gene. Complementation of the mutated
acrR gene with the wild-type gene decreased AcrA levels and produced a two- to fourfold reduction in the
fluoroquinolone MICs. None of the organic solvent-tolerant clinical isolates overexpressed another efflux-
related gene, acrE. While marA and soxS were not overexpressed, another marA homologue, ramA, was
overexpressed in 3 of 10 organic solvent-tolerant isolates. These findings indicate that multiple target and
nontarget gene changes contribute to fluoroquinolone resistance in K. pneumoniae. Besides AcrR mutations,
ramA overexpression (but not marA or soxS overexpression) was related to increased AcrAB efflux pump
expression in this collection of isolates.
Klebsiella pneumoniae is a common cause of nosocomial
infections that include urinary tract, respiratory, and wound
infections. Klebsiella spp. have been found to harbor a multi-
tude of plasmids, which confer resistance to most -lactams,
particularly the extended-spectrum cephalosporins and, more
recently, the carbapenams (33). These emerging resistance
mechanisms have dictated a shift in the strategies used to treat
infections caused by Klebsiella spp. with the fluoroquinolones
(3, 29, 32). Recent studies indicate that an increasing percent-
age of Klebsiella species are resistant to these antimicrobials
(3).
Fluoroquinolone resistance arises through specific muta-
tions within the target proteins DNA gyrase and topoisomer-
ase IV, more specifically, within a region termed the quinolo-
ne-resistance determining region (2, 5, 6). In members of the
family Enterobacteriaceae, the most common changes occur at
position 83 or 87 within DNA gyrase A and position 80 or 84
within the ParC subunit of topoisomerase IV (2, 5, 6). Muta-
tions at all the positions mentioned above have been described
in fluoroquinolone-resistant K. pneumoniae isolates (2, 5, 6, 21,
23), and a fifth mutation at position 78 in parC has recently
been identified (21).
Besides topoisomerase mutations, energy-dependent efflux
and porin loss have also been shown to confer a fluoroquino-
lone resistance phenotype in K. pneumoniae (4, 11, 21, 22).
These two changes often occur together in the majority of
multidrug-resistant Klebsiella isolates (11, 19, 21). The latter
finding may reflect the activities of chromosomal regulatory
loci like mar and sox, which cause decreased porin expression
and increased efflux pump expression (13, 17, 26). The effects
of these loci generally require a mutation within the repressor
genes of the operons or the selective binding of certain induc-
ers like salicylate (1) and paraquat (36). Mutations within
MarR, the negative regulator of the mar operon, cause over-
expression of marA in the Enterobacteriaceae, e.g., Escherichia
coli (18, 24, 26, 28, 35) and Enterobacter cloacae (17), resulting
in an antibiotic resistance phenotype. Similarly, mutations
within soxR can lead to soxS overexpression, which also results
in both organic solvent tolerance and antibiotic resistance (15,
35).
Unlike E. coli, K. pneumoniae encodes another transcrip-
tional activator, RamA, which can confer a multidrug resis-
tance phenotype when it is overexpressed in E. coli (7). RamA
is thought to form an operon with a gene specifying the outer
membrane protein RomA. RamA acts as a transcriptional
activator, while RomA is a putative channel-forming protein
(7, 14) somehow involved in the resistance phenotype. The role
of ramA in the antibiotic resistance phenotype of clinical
strains has not been described.
Studies performed with E. coli (13, 18, 26), Salmonella en-
terica subsp. enterica serovar Typhimurium (15, 31), and E.
cloacae (17) implicate both mar and sox in fluoroquinolone
resistance phenotypes through the overexpression of the mul-
tidrug efflux pump AcrAB. Mutations within the repressor
(AcrR) have also been shown to lead to acrA (34) and acrB
(35) overexpression. Complementation of the mutated acrR
with the wild-type gene was shown to decrease the level of
antibiotic resistance in E. coli, implicating the role of a func-
tional repressor in controlling the highly drug resistant pheno-
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type (34). Other efflux pumps, such as AcrEF, have also been
shown to mediate resistance in laboratory mutants of E. coli,
particularly in the absence of a functional AcrAB efflux pump
(12). The contribution of AcrEF to a resistance phenotype in
clinical isolates has not been described. In fluoroquinolone-
resistant K. pneumoniae isolates, a correlation between re-
duced levels of fluoroquinolone uptake and AcrA overexpres-
sion has been observed, although the genetic basis of this
overexpression was not described (23).
This paper investigates the roles of the mar, sox, and ram loci
and the efflux pumps AcrAB and AcrEF in the production of
the ciprofloxacin resistance phenotype observed in clinical iso-
lates of K. pneumoniae resistant to extended-spectrum cepha-
losporins.
MATERIALS AND METHODS
Bacterial strains. Thirty-three clinical K. pneumoniae strains (provided by R.
Lin, Kandang Kerbau Hospital, Singapore), selected on the basis of resistance to
extended-spectrum cephalosporins, were recovered from the following centers:
Kandang Kerbau Hospital (23 isolates), Singapore General Hospital (9 isolates),
and Alexandra Hospital (1 isolate). The identities of these clinical isolates were
reconfirmed by testing with an Analytab Products system prior to further ma-
nipulation. The laboratory strains used in this study are described in Table 1.
MICs. Testing of susceptibilities to ciprofloxacin, moxifloxacin (Bayer AG,
Wuppertal, Germany), gatifloxacin (Grunethal, GmbH, Anchen, Germany), and
TABLE 1. Laboratory strains and plasmids used in the study
Strain or plasmid Description Reference
Strains
AG100 Wild-type E. coli K-12 strain 8
AG112 MarR mutant of AG100; 5-bp deletion (from positions 1481 to 1485) 25
AG100A AG100 acrAB 27
AG100B AG100 acrR::Kan mutant 27
DJ901 E. coli GC4468 soxRS901::Tn10Kan 9, 10
JTG1078 GC4468 soxR105 zjc-2204::Tn10kan 10
KP3 K. pneumoniae, fluoroquinolone-susceptible isolate from Bacteriology Department, NEMCa This study
Plasmids
pSHA2 Tellurite resistance determinant with OmpK36 Klebsiella porin in pACYC184 20
pTS003 Tellr Chlr in pACYC184b This study
pTS003acrR pTS003 with K. pneumoniae acrR This study
a NEMC, New England Medical Center, Boston, Mass.
b Tellr, potassium tellurite resistance determinant.
TABLE 2. Primers and annealing temperatures used in the study
Gene Primer Tm (°C)a
GenBank
Accession no.
KpgyrA1 5-TGCGAGAGAAATTACACC-3 56 X16817
KpgyrA2 5-AATATGTTCCATCAGCCC-3
KpmarR1 5-CCAGCGACCTGTTTAATGA-3 56 M96235
KpmarR2 5-GCGTCATTATTACGTCTGG-3
KpmarA1 5-TGCTCAAGAAGGTCCTGCC-3 58 M96235
KpmarA2 5-TGCGGCAGCGAATAGTTTC-3
KpsoxS1 5-CCCATCAGGATATTATTCA-3 52 U00734
Kpsox2 5-AGATGTGATGGCGATAGT-3
KpacrE1 5-ATGACGACTCACGCCA-3 50 M96848
KpacrE2 5-CGTTTCACCGTCAAATG-3
KpramA1 5-GGGTCGCCGATAAGACGC-3 60 U19581
KpramA2 5-GCTGGGCGCCATTGAGTAT-3
Kpramop1 5-TATCAACGGCTGGCGGCT-3 58 U19581
Kpramop2 5-GCAGCGGTTGATGCAGGT-3
KpacrRNru1b 5-TGAGTCGCGAATTAAGCTGACAAGCTCTC-3 58 AJ318073
KpacrRBcl1c 5-TGAGTGATCAGGTCATGCTATGGTACATA-3
KpacrA1 5-ATGAACAAAAACAGAGG-3 52 AJ318073
KpacrA2 5-TTTCAACGGCAGTTTTCG-3
a Tm, melting temperature.
b Underlining indicates the Nru1 site.
c Underlining indicates the Bcl1 site.
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gentamicin (Sigma, Poole, United Kingdom) was performed by the doubling agar
dilution method as described in the guidelines of the British Society for Anti-
microbial Chemotherapy (30). The fluoroquinolone susceptibilities of the clinical
strains with and without plasmids pTS003 or pTS003acrR were determined on
Luria-Bertani agar by E-test (AB Biodisk, Solna, Sweden) or doubling agar
dilution at 37°C overnight for 18 h.
PCR. Primers specific for the quinolone-resistance determining region were
designed and used in the amplification of both the gyrA and the parC regions (5).
Primers specific for the marR, marA, soxS, and acrE genes were obtained
from the genome sequence of K. pneumoniae (http://genome.wustl.edu/projects
/bacterial/) by comparison with the homologous marRA (GenBank accession no.
M96235), soxS (GenBank accession no. U00734), and acrE (GenBank accession
no. M96848) genes of E. coli with the BLAST program. Primers specific for the
acrR and acrA sequences were obtained from the National Center for Biotech-
nology Information (GenBank accession no. AJ318073) and the K. pneumoniae
genome sequence (http://genome.wustl.edu/projects/bacterial/). The sequences
of all primers used in the study are listed in Table 2. Genomic DNA was
extracted by using the Tissue Amp kit from Qiagen, Inc., and was used as the
template for all PCRs. All PCR products were purified with the Qiaquick PCR
purification kit (Qiagen, Inc.) according to the guidelines of the manufacturer.
Bidirectional sequencing of all PCR products was performed to confirm the
mutations and the presence of the cloned genes. Sequencing of the gyrA and parC
products was performed at the Department of Hematology, Royal Infirmary of
Edinburgh; acrR, marR, and ram operator and promoter amplimers were se-
quenced at the Tufts University Core Facility.
OST. Organic solvent tolerance (OST; tolerance of hexane and pentane [Sig-
ma-Aldrich Chemical Co., Milwaukee, Wis.] and cyclohexane [Fisher Scientific])
was determined as described previously (34). The plates were incubated at 30°C
for 24 h before they were scored for growth. Strains AG100 and AG112 were
used as negative and positive controls, respectively (34).
Northern blotting analysis. The RNAeasy Bacterial kit (Qiagen, Inc.) was
used to extract RNA, with 1 to 5 g of RNA separated by electrophoresis on a
1% formaldehyde agarose gel. Hybridization was carried out with DNA probes
labeled with [-32P]dCTP (New England Nuclear, Worcester, Mass.) according
to the instructions of the manufacturer (Invitrogen Life Technologies, Carlsbad,
Calif.). For Northern blotting analysis of marA, AG100 and AG112 (a marR
mutant) served as controls; for Northern blotting analysis of soxS, DJ901 (a strain
from which soxS was deleted) and JTG1078 (a soxS-overexpressing strain) were
used as controls. For Northern blot analysis of acrA, AG100A (from which acrAB
was deleted) and AG100B (an acrR mutant) were used as controls.
Construction of acrR-complementing plasmid. The 0.7-kb acrR fragment was
amplified from the genomic DNA of a susceptible Klebsiella isolate, isolate KP3,
provided by the Bacteriology Department of the New England Medical Center,
Boston, Mass. (Table 1). Sequence analysis confirmed that the AcrR region
possessed 96% amino acid identity to the sequence in the GenBank database
(GenBank accession no. AJ318073) (see Table 4). This fragment was then re-
stricted with NruI and BclI and ligated to pACYC184, which had previously been
digested with the same enzymes. The vector pSHA2 (20), which harbors the
potassium tellurite resistance gene, was digested with NotI to release the 3-kb
resistance cassette, which was then ligated to EagI-digested pACYC184, trans-
formed into DH5 cells, and selected on potassium tellurite (25 g/ml) and
chloramphenicol (30 g/ml), thereby creating plasmid pTS003acrR. Potassium
tellurite resistance was used because of the multiresistance phenotype of the
clinical bacteria, which excluded the possibility of selection with conventional
antibiotics. The cloned wild-type acrR gene was transferred into the clinical
isolates in which an acrR mutation had been detected by electroporation of
pTS003acrR. The vector-only control was constructed by ligating the NotI-re-
stricted 3-kb potassium tellurite resistance fragment from pSHA2 to EagI-di-
gested pACYC184 to form pTS003. The effect of the cloned wild-type acrR was
examined by determining the antibiotic susceptibilities in comparison to those of
the vector-only controls and expression of AcrA (by Western blotting).
Western blotting analysis. K. pneumoniae isolates with the acrR-containing
plasmid and the corresponding wild-type strains were freshly grown in Luria-
Bertani broth to an A600 of 0.8. Twenty micrograms of total protein was loaded
for the detection of AcrA, and the proteins were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis in a 15% gel as described previously
(16). All further manipulations were performed as described previously (34).
Briefly, the membrane was blocked overnight at room temperature with 5%
dried milk and hybridized with anti-AcrA polyclonal antibody (1:8,000; gift from
H. Zgurskaya, University of Oklahoma, Norman) at room temperature for 1 h
with shaking. After three washes in wash buffer, the membrane was incubated at
room temperature for 1 h with horseradish peroxidase conjugated to anti-rabbit
immunoglobulin G (1:2,000; Life Technologies) diluted in wash buffer. The blots
were developed with Renaissance Western Blot Chemiluminescence Reagent
Plus (NEN Life Science Products, Inc., Boston, Mass.). Control strains AG100A
(from which acrAB was deleted) and AG100B (an acrR mutant with AcrA
overexpression) were used to assess the relative amounts of AcrA. Densitometric
analysis of the relative AcrA values for the clinical strains was performed both
before and after complementation with the wild-type acrR. The levels of AcrA
expression were quantified by using the National Institutes of Health Image
Program (http://rsb.info.nih.gov/nih-image/manual/index.html).
RESULTS
Antibiotic and organic solvent susceptibilities of K. pneu-
moniae isolates. Of the 33 clinical isolates tested, 19 were
FIG. 1. Northern blotting analysis of ramA expression in Klebsiella
isolates. K. pneumoniae strains (S7, S28, and S29) overproduced ramA
mRNA in comparison to the level of production by S8 (an organic
solvent-susceptible and fluoroquinolone-susceptible isolate). Northern
blotting analysis with a ramA-specific probe revealed mRNA of 0.9 kb,
signifying a polycistronic message. Lane M, molecular size marker.
TABLE 3. Topoisomerase mutations and OST in selected clinical
isolates of K. pneumoniae
Isolatea CiprofloxacinMIC (g/ml)
Amino acid at DNA
gyrase A position:
Amino acid at
topoisomerase
IV position 80
OSTb
83 87
S8 0.5 Ser3Tyr —c — 
S38 2 Ser3Tyr — — 
S28 4 Ser3Tyr — — C, P
S29 4 Ser3Leu Asp3Asn — C, P
S30 8 Ser3Tyr — — C
S37 8 Ser3Tyr — — C
S7 16 Ser3Tyr — Ser3Ile C, P
S9 16 Ser3Tyr Asp3Asn Ser3Trp 
S12 16 Ser3Ile Asp3Asn Ser3Ile 
S10 32 Ser3Tyr Asp3Asn Ser3Arg C
S27 32 Ser3Tyr Asp3Asn Ser3Ile 
S33 32 Ser3Tyr Asp3Asn Ser3Ile 
S34 32 Ser3Ile — Ser3Ile 
S5 64 Ser3Tyr Asp3Asn Ser3Ile C
S13 64 Ser3Tyr Asp3Asn Ser3Trp C
S31 64 Ser3Tyr Asp3Asn Ser3Trp 
S42 64 Ser3Tyr — — 
S6 128 Ser3Tyr Asp3Asn Ser3Arg C
S32 128 Ser3Tyr — Ser3Trp 
S36 128 Ser3Tyr Asp3Asn Ser3Trp C
a Isolates are listed by increasing ciprofloxacin MIC.
b C, resistant to cyclohexane; P, resistant to pentane; , no growth in the
presence of cyclohexane or pentane.
c —, no change at specified amino acid.
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resistant to fluoroquinolones, with MICs being greater than 4
g/ml (NCCLS guidelines) (Table 3). The efficacies of the
newer fluoroquinolones (e.g., gatifloxacin and moxifloxacin)
were comparable to those of ciprofloxacin. Twenty-four iso-
lates were resistant to gentamicin according to the NCCLS
guidelines (MICs, 16 g/ml). While all 33 isolates grew well
in the presence of hexane, 10 of the 19 fluoroquinolone-resis-
tant strains were resistant to cyclohexane and 3 were resistant
to pentane (Table 3). The OST phenotype observed for the 10
clinical isolates was not associated with resistance to a partic-
ular fluoroquinolone (Table 3).
Mutations in DNA gyrase A and ParC. The topoisomerase
mutations in 20 selected clinical strains for which ciprofloxacin
MICs were0.5 g/ml (Table 3) were generally found at Ser83
or Ser87 in GyrA and at Ser80 in ParC. The most common
mutation (in strains for which ciprofloxacin MICs were 0.5
g/ml) was Ser833Tyr in GyrA; this change was present in 17
of 20 isolates tested. The acquisition of the mutation
Asp873Asn in GyrA, observed in 11 of 20 strains, was gener-
ally associated with an increase in the fluoroquinolone MICs
and was also the only amino acid substitution observed at
position 87. Mutations in ParC, present in 13 of 20 isolates,
occurred only at position 80 and were most commonly
Ser803IIe. In two of the isolates (isolates S34 and S32), the
ParC change of Ser803Trp or IIe occurred without a change
in gyrA at position 87. None of the different amino acid sub-
stitutions was associated with a particular fluoroquinolone
MIC. Additionally, there was no correlation between the to-
poisomerase mutations, OST, and the fluoroquinolone MIC.
Expression of marA, soxS, and ramA. The overexpression of
marA, soxS, and ramA in the 10 isolates with OST and 1 isolate
(isolate S8) susceptible to fluoroquinolones and organic sol-
vents was determined by Northern blotting analysis. Of the 11
isolates investigated, none produced a transcript indicating
marA or soxS overexpression (data not shown). Sequence anal-
ysis revealed no mutations within the marR region, confirming
the results of the Northern blotting analysis. ramA overexpres-
sion was found in three organic solvent-tolerant isolates (iso-
lates S7, S28, and S29) (Fig. 1). Sequence analysis showed that
overexpression was not related to mutations within the ram
operator or promoter region.
Expression of acrA and acrE. There was a strong correlation
between the results of Northern blotting analysis of the organic
solvent-tolerant isolates and those of Western blotting analysis
with anti-AcrA antibody (Fig. 2) for all except two strains
(strains S6 and S28). These strains did not exhibit detectably
increased levels of acrA expression by Northern blotting but
produced elevated levels of AcrA (Fig. 2). As expected, or-
ganic solvent- and fluoroquinolone-susceptible isolate S8 ex-
pressed low, albeit detectable, levels of AcrA (Fig. 2). None of
the clinical isolates overproduced another efflux-related gene,
acrE, as assayed by Northern blotting with the same RNA
samples.
Genetic analysis of AcrR. Of the 10 strains sequenced and
compared to the isolate in the GenBank database (GenBank
accession no. AJ318073), one group of 5 strains (strains S6,
S28, S29, S30, and S37) harbored a series of amino acid sub-
stitutions at specific positions within the protein. Silent
changes were also present in some of the isolates (Table 4). Of
note, susceptible isolate S8 harbored the same amino acid
substitutions as the wild-type isolate used for the cloning of
acrR, isolate KP3. These findings indicated that the changes
represented genetic variation and were not linked to the OST
phenotype (Table 4 and Fig. 2). A second group of five isolates
FIG. 2. Western blotting analysis of AcrA expression by Klebsiella isolates (all isolates except S8 were organic solvent tolerant) as well as
AG100A (from which acrAB was deleted and which did not express AcrA) and AG100B (an AcrR mutant with AcrA overexpression).
Representative results of analyses performed twice are shown.
TABLE 4. Amino acid substitutions and mutations identified in AcrRa
Strain DNA change Amino acid and codon substitution or mutation
S6 7 aab substitutions P160R, G163A, F171S, R172G, L194V, F196I, K200M
S8, S30, S37 7 aa substitutions, one silent change P160R, G163A, F171S, R172G, L194V, F196I, K200M, L186L (CTG3CTT)
S28, S29 7 aa substitutions, three silent changes P160R, G163A, F171S, R172G, L194V, F196I, K200M, E146E (GAA3GAG), L186L
(CTG3CTT), L197L (CTG3TTG)
KP3 8 aa substitutions A20T, P160R, G163A, F171S, R172G, L194V, F196I, K200M
S5 11-bp deletion, frameshift mutation 144–148, TLKE
S10 11-bp deletion, frameshift mutation 144–148, TLKE
S13 11-bp deletion, frameshift mutation 144–148, TLKE
S36 11-bp deletion, frameshift mutation 144–148, TLKE
S7c 15-bp deletion 128–132, QAQRQ
a In comparison with the K. pneumoniae AcrR sequence in the GenBank database (GenBank accession no. AJ318073).
b aa, amino acid.
c S7 has the same amino acid substitutions as S6.
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consisted of four isolates (isolates S5, S10, S13, and S36) with
a 4-amino-acid deletion (TLKE; deletion of 11 bp in amino
acid positions 144 to 148) that resulted in a frameshift muta-
tion (Table 4). Pulsed-field gel electrophoresis of the isolates in
the second subgroup showed they were not clonal (data not
shown). A fifth isolate (isolate S7), which produced high levels
of AcrA, contained a 5-amino-acid deletion (QAQRQ; dele-
tion of 15 bp in amino acid positions 128 to 132) at positions
that differed from the positions at which bases were deleted in
the other four isolates (Table 4 and Fig. 2). Isolate S7 harbored
the same genetic variation seen in the isolates in the first group
with OST (Table 4).
acrR complementation. Trans-complementation of strains
bearing the mutated acrR gene with the wild-type gene resulted
in two- to fourfold decreases in the MICs of norfloxacin and
ciprofloxacin (Table 5). Decreased AcrA levels were seen by
Western blotting and densitometry, indicating that the wild-
type acrR was able to down-regulate AcrA expression (Fig. 3).
DISCUSSION
In the K. pneumoniae clinical isolates studied, mutations
associated with fluoroquinolone resistance occurred in both
GyrA and ParC at positions identified previously (5, 6, 11, 19,
21, 23). Mutations in gyrA were observed in isolates for which
the ciprofloxacin MIC was 0.5 g/ml and greater, and isolates
for which the MIC was 16 g/ml were found to have an
additional mutation within parC. Unlike E. coli, Klebsiella does
not appear to require the presence of double mutations in both
gyrA and parC for higher levels of fluoroquinolone resistance.
Three mutations appeared to be sufficient for high-level resis-
tance (Table 3). While the possible involvement of other genes,
namely, gyrB and parE, was not investigated, the role of mu-
tations in these genes in mediating high-level fluoroquinolone
resistance has not been described among the other members of
the family Enterobacteriaceae (34).
Like others, our studies show that the topoisomerase muta-
tions alone were not able to explain the wide range of fluoro-
quinolone susceptibilities observed for clinically resistant iso-
lates (25, 26). Studies with clinical E. coli isolates have shown
that increased levels of marA expression (25, 35) are associated
with increased levels of fluoroquinolone resistance. None of
the Klebsiella isolates evaluated in this study harbored a mu-
tation within marR, and none exhibited marA overexpression.
FIG. 3. Effect of wild-type acrR on expression of AcrA. White bars, AcrA expression in acrR mutant clinical K. pneumoniae isolates; gray bars,
strains complemented with wild-type Klebsiella acrR (pTS003acrR). E. coli AG100B (acrR mutant) served as a positive control.
TABLE 5. Effect of complementation with wild-type AcrR on
fluoroquinolone susceptibility
Straina
MIC (g/ml)b
Norfloxacin Ciprofloxacin
S5 256 64
S5/pTS003acrR 96 8
S5/pTS003 128 64
S10 256 64
S10/pTS003acrR 64 8
S10/pTS003 128 64
S13 256 128
S13/pTS003acrR 256 64
S13/pTS003 256 128
S36 256 128
S36/pTS003acrR 192 64
S36/pTS003 256 128
S7 96 8
S7/pTS003acrR 64 2
S7/pTS003 64 8
a pTS003acrR is the vector containing Klebsiella acrR; pTS003 contains the
vector only.
b MIC were determined by E-test (norfloxacin) and doubling agar dilutions
(ciprofloxacin).
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Similarly, no soxS overexpression was detected by Northern
blotting analysis. Interestingly, increased levels of expression of
the related Klebsiella transcriptional regulator ramA were seen
in 3 of the 11 isolates studied. All three isolates also overex-
pressed AcrA, the membrane fusion protein of the AcrAB-
TolC efflux pump. The ramA operator and promoter sequences
of the three ramA-overexpressing strains did not show any
changes within this region, suggesting that ramA overexpres-
sion is mediated by a different locus. An increased level of
transcription of acrA follows increased levels of expression of
regulatory genes marA and soxS, even in the presence of a
functioning AcrR. Heterologous expression of ramA in E. coli
conferred a multidrug resistance phenotype which was depen-
dent on a functional AcrAB pump (T. Schneiders and S. B.
Levy, unpublished data). These findings suggest that the over-
expression of AcrA is linked to the increased level of transcrip-
tion of ramA. One of the strains which overexpressed ramA
(strain S7) also harbored a deletion within AcrR, so the role of
ramA in fluoroquinolone resistance in this isolate is unclear.
Western blotting analysis of AcrA showed overexpression of
AcrA which was associated with acrR mutations in some of the
isolates. Five isolates harbored the same 7-amino-acid substi-
tutions with or without silent changes in AcrR not related to
altered levels of AcrA expression (Table 4). This finding indi-
cates that genotypic variation exists between geographically
different clinical isolates and is consistent with the recent find-
ing of at least a 5% amino acid variation between the acrA
GenBank entry (A. Domenech-Sanchez et al., Abstr. 41st In-
tersci. Conf. Antimicrob. Agents Chemother., abstr. C1-2018,
p. 104, 2000) and ciprofloxacin-resistant Klebsiella isolates re-
covered in Italy (23).
Five strains with OST showed acrR deletions (Fig. 4). These
mutations are different from those described in the E. coli
AcrR (34) (Fig. 4). A conserved cluster was consistently de-
leted (TLKE; deletion of 11 bp in amino acid positions 144 to
148), albeit in only four of the clinical isolates; but the strains
were not confined to one hospital in Singapore, nor were they
found to be clonally related, as determined by pulsed-field gel
electrophoresis (data not shown). Finally, the acrR deletions
described here do not confer a particular level of resistance to
ciprofloxacin, as the MICs for these isolates ranged from 16 to
128 g/ml. Of particular interest is high-level fluoroquinolone-
resistant (128 g/ml) and organic solvent-tolerant isolate S6,
which harbored three topoisomerase mutations (two in gyrA
DNA and one in parC DNA) and produced increased levels of
AcrA but which had no mutations within the repressor gene
(AcrR) and did not have increased levels of expression of any
of the regulatory genes investigated. It is likely that other
regulatory genes are involved. Complementation with the plas-
mid containing wild-type acrR resulted in decreases in the
MICs of both ciprofloxacin and norfloxacin for all acrR dele-
tion mutants tested (Table 4). This study and other published
data clearly establish a role for efflux pumps such as AcrAB in
clinical fluoroquinolone resistance. However, the trend ap-
pears to favor the selection of topoisomerase (gyrA) mutations
prior to the selection of those contributing to efflux pump
overexpression. The results presented here support the role of
acrR mutations and the regulatory locus ramA in mediating
AcrA overexpression and fluoroquinolone resistance in K.
pneumoniae.
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